Gastar menos não é gastar melhor: o medicamento no OE de 2027

When a patient leaves a consultation with a prescription in hand, they rarely think about the State Budget. And yet, the answers to questions such as "Is this medicine available?", "How much does it cost?", or "When will it arrive?" begin to take shape much earlier, in public accounts.

In her latest opinion article for Observador, our partner and Life Sciences specialist, Patrícia Paias, analyses the proposed 2027 State Budget and highlights key warnings regarding pharmaceutical policy in Portugal:

• Access to innovation in Portugal faces three main challenges: delays in access, a lack of predictability in sectoral rules, and insufficient prevention of medicine shortages.

• Cost savings are essential, but they must not compromise timely access to innovative treatments.

Full article below.